Sutro Biopharma, Inc. (STRO) Key Metrics
STRO valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $181.4M
- Enterprise value
- $113.9M
- P/E (TTM)
- —
- Forward P/E
- 10.0
- PEG ratio
- —
- Price / sales
- 4.0 10-yr median 4.2
- Price / book
- 2.1 10-yr median 2.7
- EV / EBITDA
- 41.7
- Dividend yield
- —
- Beta
- 1.50
STRO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSTRO valuation Price multiples at each fiscal year-end price.
Price / sales−57.9%
1.0
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−44.3 pts
−182.0%
2025 · hover or tap a bar for each year
20162025
STRO returns How much profit the business earns on the capital it uses.
Return on assets−15.1 pts
−68.1%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+139.1 pts
−174.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover+152.6%
0.37
2025 · hover or tap a bar for each year
20162025
STRO per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+49.3%
$12.06
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$22.49
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$21.06
2025 · hover or tap a bar for each year
20162025
Book value per share
−$15.59
2025 · hover or tap a bar for each year
20162025
Shares outstanding+10.6%
8.5M
2025 · hover or tap a bar for each year
20162025
STRO financial health Debt, liquidity and how easily interest is covered.
Net debt+$168.0M
−$125.8M
2025 · hover or tap a bar for each year
20162025
Current ratio−22.8%
2.01
2025 · hover or tap a bar for each year
20162025
Interest coverage
-2.7
2025 · hover or tap a bar for each year
20162025
Debt / assets+50.8%
0.09
2025 · hover or tap a bar for each year
20162025
STRO efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−109 days
22 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−54 days
450 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−55 days
-427 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue−3.3 pts
1.7%
2025 · hover or tap a bar for each year
20162025
STRO valuation history
Fiscal year-endToday10-year median
STRO returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
STRO debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
STRO cash returned to shareholders
DividendsBuybacksFree cash flow
STRO price vs earnings per share
Share price at year-endEPS (right axis)
STRO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $98.3M | $141.4M | $258.1M | $410.0M | $686.3M | $7.07B | — | — | — | — |
| Enterprise value | −$27.4M | −$152.4M | −$83.9M | $130.6M | $545.7M | $6.74B | — | — | — | — |
| Price / sales | 1.0 | 2.3 | 1.7 | 6.0 | 11.1 | 165.5 | — | — | — | — |
| Price / book | — | 3.2 | 1.7 | 1.9 | 2.7 | 21.3 | — | — | — | — |
| Price / operating cash flow | — | — | — | 115.5 | — | — | — | — | — | — |
| EV / sales | -0.3 | -2.5 | -0.5 | 1.9 | 8.8 | 157.7 | — | — | — | — |
| Earnings yield | −194.4% | −160.9% | −41.4% | −29.1% | −15.4% | −0.5% | — | — | — | — |
| Free cash flow yield | −182.0% | −137.7% | −44.9% | −1.1% | −14.1% | −1.1% | — | — | — | — |
| Dividend yield | — | — | — | 0.1% | — | 0.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.2% | 0.2% | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $11.57 | $18.40 | $42.90 | $80.80 | $148.80 | $217.10 | $110.00 | $90.20 | — | — |
| Per share | ||||||||||
| Revenue per share | $12.06 | $8.08 | $25.55 | $13.36 | $13.42 | $1.31 | — | — | $7.39 | — |
| Earnings per share | −$22.49 | −$29.61 | −$17.75 | −$23.49 | −$22.88 | −$0.99 | — | — | −$2.81 | — |
| Operating cash flow per share | −$20.86 | −$24.93 | −$18.55 | $0.70 | −$17.71 | −$2.08 | — | — | −$5.30 | — |
| Free cash flow per share | −$21.06 | −$25.33 | −$19.27 | −$0.85 | −$21.03 | −$2.30 | — | — | −$5.77 | — |
| Cash per share | $16.64 | $41.25 | $62.43 | $65.90 | $42.92 | $11.30 | — | — | $3.15 | — |
| Book value per share | −$15.59 | $5.81 | $24.87 | $42.78 | $54.76 | $10.19 | — | — | −$15.58 | — |
| Tangible book value per share | −$15.59 | $5.81 | $24.87 | $42.78 | $54.76 | $10.19 | — | — | −$15.58 | — |
| Dividends per share | — | — | — | $0.09 | — | $0.01 | — | — | — | — |
| Capex per share | $0.20 | $0.40 | $0.72 | $1.55 | $3.32 | $0.22 | — | — | $0.47 | — |
| Debt per share | $1.84 | $3.01 | $5.59 | $10.84 | $12.44 | $1.02 | — | — | $2.34 | — |
| Shares outstanding | 8.5M | 7.7M | 6.0M | 5.1M | 4.6M | 32.6M | — | — | 7.0M | — |
| Change in shares outstanding | +10.6% | +27.7% | +18.6% | +10.0% | −85.8% | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | −234.2% | −58.2% | −50.8% | −36.1% | −14.9% | −48.6% | −313.4% | — | — |
| Return on invested capital (ROIC) | — | — | — | — | −142.4% | — | — | — | — | — |
| Return on assets (ROA) | −68.1% | −53.0% | −24.3% | −31.9% | −28.7% | −11.7% | −29.4% | −26.8% | −35.8% | 2.5% |
| Return on tangible assets | −109.9% | −58.7% | −22.7% | −29.3% | −30.9% | −8.2% | −35.6% | −15.8% | −48.3% | 2.5% |
| Free cash flow margin | −174.6% | −313.7% | −75.4% | −6.4% | −156.8% | −175.4% | −160.3% | 29.0% | −78.1% | −29.4% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | — | −7.73 |
| Financial health | ||||||||||
| Total debt | $15.7M | $23.2M | $33.6M | $55.0M | $57.4M | $33.4M | $9.9M | $14.7M | $16.3M | $1.2M |
| Cash & short-term investments | $141.4M | $316.9M | $375.6M | $334.4M | $197.9M | $368.1M | $117.9M | $204.5M | $22.0M | $47.5M |
| Net debt | −$125.8M | −$293.7M | −$342.0M | −$279.3M | −$140.6M | −$334.8M | −$108.0M | −$189.8M | −$5.7M | −$46.3M |
| Debt / equity | — | 0.52 | 0.22 | 0.25 | 0.23 | 0.10 | 0.10 | 0.11 | — | — |
| Debt / assets | 0.09 | 0.06 | 0.07 | 0.14 | 0.17 | 0.08 | 0.06 | 0.07 | 0.40 | 0.02 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | — | −6.29 |
| Current ratio | 2.01 | 2.60 | 4.50 | 5.31 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Quick ratio | 2.01 | 2.60 | 4.50 | 5.48 | 5.24 | 12.78 | 3.90 | 5.76 | 0.80 | 0.99 |
| Interest coverage | -2.7 | -7.7 | -3.8 | -38.5 | -31.4 | -17.9 | -12.8 | -23.3 | -28.0 | — |
| Working capital | $75.8M | $211.4M | $327.8M | $286.6M | $176.8M | $348.6M | $95.6M | $173.5M | −$6.3M | −$493,000 |
| Invested capital | −$258.2M | −$249.1M | −$192.3M | −$62.3M | $112.0M | −$2.7M | −$10.2M | −$58.2M | −$114.7M | −$137.2M |
| Tangible asset value | −$132.5M | $44.6M | $149.6M | $217.0M | $252.6M | $332.0M | $97.8M | $131.5M | −$109.0M | −$90.9M |
| Net current asset value | −$155.4M | $704,000 | $100.5M | $163.3M | $129.7M | $316.1M | $70.0M | $118.3M | −$124.1M | −$110.5M |
| Graham net-net per share | −$19.05 | −$2.51 | $13.56 | $28.38 | $25.68 | $9.52 | — | — | −$18.08 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $463,000 | — | $314,000 | $297,000 | — | — | — |
| Share buybacks (net) | — | — | $490,000 | $463,000 | $7,000 | $314,000 | $327,000 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | 0.0% | — | — |
| Capex / revenue | 1.7% | 5.0% | 2.8% | 11.6% | 24.8% | 16.7% | 8.1% | 4.1% | 6.4% | 7.4% |
| Capex / operating cash flow | — | — | — | 221.4% | — | — | — | 12.3% | — | — |
| Capex / depreciation | 0.23 | 0.43 | 0.63 | 1.38 | 3.16 | 1.66 | 0.73 | 0.34 | 0.66 | 0.78 |
| Stock-based compensation / revenue | 13.7% | 39.8% | 16.2% | 38.8% | 37.6% | 27.9% | 24.1% | 7.5% | 2.7% | 1.6% |
| R&D / revenue | 162.4% | 406.2% | 117.4% | 202.4% | 168.7% | 180.1% | 153.5% | 141.2% | 105.6% | 72.9% |
| SG&A / revenue | 40.0% | 78.1% | 40.7% | 87.9% | 90.5% | 86.2% | 76.3% | 55.6% | 31.6% | 24.8% |
| Efficiency | ||||||||||
| Days sales outstanding | 22.4 | 131.5 | 51.3 | 52.7 | 53.1 | 50.7 | 37.5 | 19.5 | 7.8 | 3.5 |
| Days of inventory on hand | — | — | -312.4 | -256.9 | 0.0 | — | — | 0.0 | — | — |
| Days payables outstanding | 449.5 | 503.5 | 381.2 | 237.9 | 215.7 | 26.4 | 24.0 | 20.1 | 22.1 | 28.4 |
| Cash conversion cycle (days) | -427.1 | -372.1 | -642.3 | -442.1 | -162.6 | 24.3 | 13.5 | -0.5 | -14.4 | -24.9 |
| Receivables turnover | 16.28 | 2.78 | 7.12 | 6.92 | 6.87 | 7.21 | 9.73 | 18.68 | 47.02 | 103.52 |
| Payables turnover | 0.81 | 0.72 | 0.96 | 1.53 | 1.69 | 13.83 | 15.18 | 18.20 | 16.49 | 12.83 |
| Inventory turnover | — | — | — | — | 9,773,000.00 | — | — | 54,262,000.00 | — | — |
| Asset turnover | 0.37 | 0.14 | 0.35 | 0.18 | 0.17 | 0.16 | 0.23 | 0.29 | 0.94 | 0.86 |
| Average receivables | $6.3M | $22.3M | $21.6M | $9.8M | $9.0M | $5.9M | $4.4M | $2.1M | $1.1M | $577,000 |
| Average payables | $9.0M | $10.0M | $7.1M | $5.4M | $5.8M | $5.6M | $4.3M | $3.0M | $3.1M | $3.4M |
| Average inventory | — | — | −$5.8M | −$5.8M | $1 | — | — | $1 | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from STRO's annual financial statements (latest annual report filed March 23, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
STRO valuation and financial ratios
It ended the year with $15.7 million of debt and $141.4 million in cash and short-term investments, a net cash position of $125.8 million.
See the STRO income statement, the STRO chart for price history, or the STRO stock overview for the latest quote and news.
STRO key metrics FAQ
How much debt does Sutro Biopharma have?
Sutro Biopharma had total debt of $15.7 million at the end of fiscal 2025 and more cash than debt.
What is Sutro Biopharma's free cash flow yield?
Sutro Biopharma generated -$178.9 million of free cash flow in fiscal 2025, a free cash flow yield of −182.0% on its market value at year-end ($98.3 million).
What is Sutro Biopharma's current ratio?
Sutro Biopharma's current ratio was 2.01 at the end of fiscal 2025: current assets were 2.01 times current liabilities.